+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Latin America Chlorpheniramine Maleate Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 140 Pages
  • June 2024
  • Region: Latin America
  • Expert Market Research
  • ID: 5984390
The global chlorpheniramine maleate market was valued at USD 514.9 million in 2023, with Latin America holding a significant market share. The market is driven by the rising prevalence of allergic conditions. It is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to attain USD 848.1 million by 2032.

Latin America Chlorpheniramine Maleate Market Outlook

  • Recent data reveals that allergic rhinitis is one the most prevalent chronic diseases in the world, affecting 10-40% of the world’s population. Out of this, Latin America covers a significant population segment. This high prevalence of allergic conditions directly impacts the market demand for effective antihistamines such as chlorpheniramine maleate.
  • One of the major Latin America chlorpheniramine maleate market trends is the rise in self-medication practices, particularly with over-the-counter (OTC) medicinal products such as chlorpheniramine maleate. In Brazil, self-medication prevalence rates are reported to range from 16.1% to 35.0%, with OTC drugs representing over 25% of the volume of marketed medicines.
  • In Brazil, around 10.9% of the total population is represented by people aged 65 or older. The rising aging population which is more prone to developing an allergic condition is poised to bolster the market share for antihistamine drugs.

Latin America Chlorpheniramine Maleate Market Analysis

Chlorpheniramine maleate is the first-generation class of antihistamines primarily used to relieve symptoms associated with allergies and the common cold. It is available in the form of tablets, syrups, or even extended-release capsules. The medication works by blocking histamine, a substance in the body that causes symptoms of allergies, such as a runny nose or sneezing. The heightened awareness about allergy management, due to public health campaigns and improved healthcare services, is prompting people to seek treatment for allergy symptoms, thereby driving the Latin America chlorpheniramine maleate market growth.

The market is influenced by the increased prevalence of allergic conditions such as allergic rhinitis or seasonal allergies. Recent data reveals that allergic rhinitis is one the most prevalent chronic diseases in the world, affecting more than 400 million people and observed in 10-40% of the world’s population. Latin America also experiences a high burden of this allergic condition, significantly impacting the quality of life and impairing development in children. The high prevalence of allergic rhinitis fuels the demand for effective and affordable antihistamines to manage the symptoms which is likely to augment the Latin America chlorpheniramine maleate market demand.

One of the major market trends is the increase in self-medication practices particularly with non-prescription or over-the-counter medicinal products including chlorpheniramine maleate medication. In Brazil, the prevalence rates of self-medication are reported to range from 16.1% to 35.0%. Moreover, the demand for over-the-counter drugs is increasing in the region, representing over 25% of the volume of marketed medicines. Since chlorpheniramine maleate is widely available as an over the counter and low-cost generic, the market share for the medication is expected to increase with the growing preference for self-care services and affordable treatment options.

The Latin America chlorpheniramine maleate market share is also influenced by the rising aging population which is more prone to developing an allergic condition. In Brazil, around 10.9% of the total population is represented by people aged 65 or older. The increase in the number of people in this age group is poised to bolster the demand for antihistamine drugs. Further, the rapid expansion of pharmaceutical distribution channels, including online pharmacies, is facilitating easier access to chlorpheniramine maleate products, which is anticipated to boost market growth in the forecast period.

Latin America Chlorpheniramine Maleate Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Market Breakup by Dosage Form

  • Tablets
  • Syrup
  • Eye Drops
  • Others

Market Breakup by Application

  • Allergy
  • Hay Fever (Allergic Rhinitis)
  • Common Cold
  • Watery Eyes
  • Itchy Throat/Skin
  • Anaphylactic Shock
  • Urticaria

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Country

  • Brazil
  • Argentina
  • Mexico
  • Others

Latin America Chlorpheniramine Maleate Market: Competitor Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Bayer AG
  • Novartis AG
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck
  • Roche
  • Teva Pharmaceutical Industries Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Latin America chlorpheniramine maleate market forecast outlook for 2024-2032?
The Latin America chlorpheniramine maleate market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 848.1 million by 2032.

What are the major factors aiding the Latin America chlorpheniramine maleate market demand?
The rising prevalence of allergic conditions along with awareness to manage such conditions effectively is fuelling the demand for the market.

What are the major Latin America chlorpheniramine maleate market trends?
One of the significant trends in the market is the rise in self-medication practices, particularly with over the counter (OTC) medicinal products such as chlorpheniramine maleate. In Brazil, the self-medication prevalence rate is reported to range from 16.1% to 35.0%, with OTC drugs representing over 25% of the volume of marketed medicines.

What is the market segmentation based on the dosage form?
Based on the dosage form, the market is segmented into tablets, syrup, and eye drops, among others.

What are the major distribution channels of the market?
Distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies.

What are the applications of chlorpheniramine maleate?
Major applications areas of include allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria.

What is the market segmentation by countries?
The market segmentation by countries includes Brazil, Argentina, and Mexico, among others.

Who are the key players involved in the Latin America chlorpheniramine maleate market?
The key players in the market are Bayer AG, Novartis AG, Sanofi, Johnson & Johnson, Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Merck, Roche, and Teva Pharmaceutical Industries Ltd.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Latin America Chlorpheniramine Maleate Market Overview
3.1 Latin America Chlorpheniramine Maleate Market Historical Value (2017-2023)
3.2 Latin America Chlorpheniramine Maleate Market Forecast Value (2024-2032)
4 Latin America Chlorpheniramine Maleate Market Landscape*
4.1 Latin America Chlorpheniramine Maleate: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Latin America Chlorpheniramine Maleate: Product Landscape
4.2.1 Analysis by Dosage Form
4.2.2 Analysis by Application
5 Latin America Chlorpheniramine Maleate Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Chlorpheniramine Maleate Market Segmentation (2017-2032)
6.1 Latin America Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
6.1.1 Market Overview
6.1.2 Tablets
6.1.3 Syrup
6.1.4 Eye Drops
6.1.5 Others
6.2 Latin America Chlorpheniramine Maleate Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Allergy
6.2.3 Hay Fever (Allergic Rhinitis)
6.2.4 Common Cold
6.2.5 Watery Eyes
6.2.6 Itchy Throat/Skin
6.2.7 Anaphylactic Shock
6.2.8 Urticaria
6.3 Latin America Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Online Pharmacies
6.4 Latin America Chlorpheniramine Maleate Market (2017-2032) by Country
6.4.1 Market Overview
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Others
7 Brazil Chlorpheniramine Maleate Market (2017-2032)
7.1 Brazil Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
7.1.1 Market Overview
7.1.2 Tablets
7.1.3 Syrup
7.1.4 Eye Drops
7.1.5 Others
7.2 Brazil Chlorpheniramine Maleate Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Allergy
7.2.3 Hay Fever (Allergic Rhinitis)
7.2.4 Common Cold
7.2.5 Watery Eyes
7.2.6 Itchy Throat/Skin
7.2.7 Anaphylactic Shock
7.2.8 Urticaria
7.3 Brazil Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
7.3.1 Market Overview
7.3.2 Hospital Pharmacies
7.3.3 Retail Pharmacies
7.3.4 Online Pharmacies
8 Argentina Chlorpheniramine Maleate Market (2017-2032)
8.1 Argentina Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
8.1.1 Market Overview
8.1.2 Tablets
8.1.3 Syrup
8.1.4 Eye Drops
8.1.5 Others
8.2 Argentina Chlorpheniramine Maleate Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Allergy
8.2.3 Hay Fever (Allergic Rhinitis)
8.2.4 Common Cold
8.2.5 Watery Eyes
8.2.6 Itchy Throat/Skin
8.2.7 Anaphylactic Shock
8.2.8 Urticaria
8.3 Argentina Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
8.3.1 Market Overview
8.3.2 Hospital Pharmacies
8.3.3 Retail Pharmacies
8.3.4 Online Pharmacies
9 Mexico Chlorpheniramine Maleate Market (2017-2032)
9.1 Mexico Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
9.1.1 Market Overview
9.1.2 Tablets
9.1.3 Syrup
9.1.4 Eye Drops
9.1.5 Others
9.2 Mexico Chlorpheniramine Maleate Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Allergy
9.2.3 Hay Fever (Allergic Rhinitis)
9.2.4 Common Cold
9.2.5 Watery Eyes
9.2.6 Itchy Throat/Skin
9.2.7 Anaphylactic Shock
9.2.8 Urticaria
9.3 Mexico Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
9.3.1 Market Overview
9.3.2 Hospital Pharmacies
9.3.3 Retail Pharmacies
9.3.4 Online Pharmacies
10 Regulatory Framework
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Bayer AG
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Novartis AG
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Sanofi
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Johnson & Johnson
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Pfizer
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Boehringer Ingelheim
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 GlaxoSmithKline
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Merck
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Roche
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Teva Pharmaceutical Industries Ltd.
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 Latin America Chlorpheniramine Maleate Market - Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Bayer AG
  • Novartis AG
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Merck
  • Roche
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information